Kim, B.-K.; Eah, K.Y.; Park, J.-M. Essential Thrombocythemia and Ischemic Stroke: A Case Series of Five JAK2-Positive Patients. Medicina2023, 59, 1300.
Kim, B.-K.; Eah, K.Y.; Park, J.-M. Essential Thrombocythemia and Ischemic Stroke: A Case Series of Five JAK2-Positive Patients. Medicina 2023, 59, 1300.
Kim, B.-K.; Eah, K.Y.; Park, J.-M. Essential Thrombocythemia and Ischemic Stroke: A Case Series of Five JAK2-Positive Patients. Medicina2023, 59, 1300.
Kim, B.-K.; Eah, K.Y.; Park, J.-M. Essential Thrombocythemia and Ischemic Stroke: A Case Series of Five JAK2-Positive Patients. Medicina 2023, 59, 1300.
Abstract
Objectives: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by elevated platelet counts and an increased risk of thrombotic events, including ischemic strokes. Methods: We conducted a retrospective analysis of data from consecutive ischemic stroke patients with ET between March 2014 and February 2023. Results: This case series describes the clinical presentation, radiological features, and management of five patients with ET-associated ischemic strokes, all harboring the JAK2 mutation. The diverse radiological findings suggest that both large and small vessel diseases may be influenced by the prothrombotic state induced by ET. A significant elevation in platelet count was observed to correlate with the emergence of new acute infarctions in some cases. Conclusions: The study highlights combined use of antiplatelet and cytoreductive therapy in preventing secondary stroke events in patients with ET and JAK2 mutations. The heterogeneity of stroke patterns in this population necessitates a comprehensive understanding of the underlying pathophysiological mechanisms and tailored therapeutic approaches.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
